Skip to main content
. 2020 Apr 15;23(4):e25484. doi: 10.1002/jia2.25484

Figure 2.

Figure 2

Weight over the first two years of ART among PWH starting INSTI‐based regimens. ART, antiretroviral therapy; DTG, dolutegravir; EVG, elvitegravir; INSTI, integrase strand transfer inhibitors; PWH, persons with HIV; RAL, raltegravir.